Vladdy's Laser Eye Surgery Is the Only Blue Jays Story That Actually Matters

The Toronto Blue Jays finished 79-83 in 2026, dead last in the AL East, one season after winning the American League pennant. There are a dozen ways to explain that collapse — ten players ended the year on the 60-day injured list, the offense lost 52 home runs and 204 runs off its 2025 production, and a franchise that posted a +107 run differential a year ago finished at minus-46.

But only one offseason development genuinely changes the team's trajectory, and it arrived this week: Vladimir Guerrero Jr. reportedly underwent laser eye surgery, with the hope being that it corrects whatever was wrong during a career-worst season.

The numbers behind the power outage

Guerrero hit .260/.332/.356 in 2026 with 9 home runs and 57 RBI over 144 games. He struck out 81 times against 56 walks. His .688 OPS was the lowest of his career, and it came one season after he posted a .292/.381/.467 line with 23 homers, 84 RBI, 96 runs and an .848 OPS.

The 9 home runs are the headline. In his eight MLB seasons, Guerrero has averaged 28. A first baseman with a sub-.360 slugging percentage isn't just underperforming — he's unusable in the middle of a lineup. He acknowledged as much during the season, telling reporters that his $500 million contract was on his mind "every at-bat I fail."

Whether vision explains the lost power is unknowable from the outside. What's clear is that the organization is treating it as a real factor rather than bad luck. Both GM Ross Atkins and president Mark Shapiro have publicly said they have "no doubt" Guerrero will rediscover his form in 2027, and the surgery gives that optimism something concrete to stand on — a correctable cause rather than an open-ended slump.

Why one bat can't fix everything

Even a full Guerrero rebound doesn't solve Toronto's problems. The 2026 offense hit .248 as a team with a .692 OPS, down from .264 and .760 the year before. Hits fell from 1,434 to 1,210. Total bases dropped from 2,317 to 1,864. This wasn't a one-man failure.

Kazuma Okamoto was the counterexample. The Japanese rookie slugger hit 33 home runs with 92 RBI in 156 games, earned Baseball America's All-Rookie nod at third base, and posted a barrel rate in the 90th percentile. His issues are also clear: a 183-strikeout season and a strikeout percentile in the bottom tenth of the league. He's a middle-of-the-order power source, not a contact stabilizer.

Pitching, meanwhile, actually improved. Toronto's team ERA dropped from 4.12 to 3.87, and the bullpen posted a 2.57 ERA with a 1.185 WHIP. The problem was never preventing runs — it was scoring them.

What it means for 2027

The Blue Jays need rotation depth, second base, outfield help and bullpen arms this winter, per the roster-needs analysis floating around the club. They'll also get healthier, with Patrick Corbin, José Berríos, Anthony Santander, Addison Barger and Yimi García among those who spent the year on the 60-day IL.

But here's the uncomfortable arithmetic: if Guerrero returns to his 2025 form, Toronto's lineup has a functioning centerpiece and a serious chance to contend. If he doesn't, no amount of offseason traffic fixes a team whose highest-paid hitter slugged .356.

That's why the eye surgery is the story of the week. Not because it guarantees anything — it doesn't — but because the Blue Jays' entire 2027 outlook is now tied to whether a medical procedure can explain away the worst season of a franchise player's career.